RU2018130866A - Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений - Google Patents
Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений Download PDFInfo
- Publication number
- RU2018130866A RU2018130866A RU2018130866A RU2018130866A RU2018130866A RU 2018130866 A RU2018130866 A RU 2018130866A RU 2018130866 A RU2018130866 A RU 2018130866A RU 2018130866 A RU2018130866 A RU 2018130866A RU 2018130866 A RU2018130866 A RU 2018130866A
- Authority
- RU
- Russia
- Prior art keywords
- history
- biomarkers
- group
- subject
- status
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 42
- 208000024172 Cardiovascular disease Diseases 0.000 title claims 12
- 239000000090 biomarker Substances 0.000 claims 43
- 208000010125 myocardial infarction Diseases 0.000 claims 32
- 238000004393 prognosis Methods 0.000 claims 15
- 102000004264 Osteopontin Human genes 0.000 claims 14
- 108010081689 Osteopontin Proteins 0.000 claims 14
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 12
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 claims 12
- 210000004556 brain Anatomy 0.000 claims 12
- 239000002934 diuretic Substances 0.000 claims 12
- 230000001452 natriuretic effect Effects 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 108010076365 Adiponectin Proteins 0.000 claims 11
- 102000011690 Adiponectin Human genes 0.000 claims 11
- 210000004351 coronary vessel Anatomy 0.000 claims 11
- 238000003745 diagnosis Methods 0.000 claims 11
- 210000003734 kidney Anatomy 0.000 claims 10
- 238000011160 research Methods 0.000 claims 10
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 9
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 102000007592 Apolipoproteins Human genes 0.000 claims 8
- 108010071619 Apolipoproteins Proteins 0.000 claims 8
- 208000029078 coronary artery disease Diseases 0.000 claims 8
- 230000000414 obstructive effect Effects 0.000 claims 8
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 7
- 238000013146 percutaneous coronary intervention Methods 0.000 claims 7
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 6
- 101710188053 Protein D Proteins 0.000 claims 6
- 101710132893 Resolvase Proteins 0.000 claims 6
- 238000002399 angioplasty Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000001631 haemodialysis Methods 0.000 claims 6
- 230000000322 hemodialysis Effects 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 102000004237 Decorin Human genes 0.000 claims 5
- 108090000738 Decorin Proteins 0.000 claims 5
- 102000004890 Interleukin-8 Human genes 0.000 claims 5
- 108090001007 Interleukin-8 Proteins 0.000 claims 5
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 5
- 102000036675 Myoglobin Human genes 0.000 claims 5
- 108010062374 Myoglobin Proteins 0.000 claims 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims 5
- 238000009434 installation Methods 0.000 claims 5
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 5
- 229940096397 interleukin-8 Drugs 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 238000007887 coronary angioplasty Methods 0.000 claims 4
- 230000003511 endothelial effect Effects 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 229940084845 Metalloproteinase-1 inhibitor Drugs 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- -1 midkin Proteins 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 150000002823 nitrates Chemical class 0.000 claims 2
- 238000004445 quantitative analysis Methods 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims 1
- 238000002583 angiography Methods 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007435 diagnostic evaluation Methods 0.000 claims 1
- 210000003989 endothelium vascular Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4884—Other medical applications inducing physiological or psychological stress, e.g. applications for stress testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289513P | 2016-02-01 | 2016-02-01 | |
| US62/289,513 | 2016-02-01 | ||
| US201662378535P | 2016-08-23 | 2016-08-23 | |
| US62/378,535 | 2016-08-23 | ||
| PCT/US2017/016081 WO2017136464A1 (en) | 2016-02-01 | 2017-02-01 | Diagnostic and prognostic methods for cardiovascular diseases and events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018130866A true RU2018130866A (ru) | 2020-03-04 |
Family
ID=59500904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018130866A RU2018130866A (ru) | 2016-02-01 | 2017-02-01 | Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10983135B2 (enExample) |
| EP (2) | EP4574024A3 (enExample) |
| JP (4) | JP7134870B2 (enExample) |
| KR (1) | KR20180101595A (enExample) |
| CN (2) | CN108700596A (enExample) |
| AU (1) | AU2017214469A1 (enExample) |
| BR (1) | BR112018015698A2 (enExample) |
| CA (1) | CA3012192A1 (enExample) |
| MA (1) | MA43980A (enExample) |
| MX (1) | MX2018009304A (enExample) |
| RU (1) | RU2018130866A (enExample) |
| SG (1) | SG11201805906WA (enExample) |
| WO (1) | WO2017136464A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791191C1 (ru) * | 2022-12-26 | 2023-03-03 | Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации | Способ оценки клинической значимости фибрилляции предсердий при определении показаний к интервенционному лечению фибрилляции предсердий |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108700596A (zh) | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| EP3682240B1 (en) * | 2017-09-14 | 2024-01-24 | Laboratory Corporation of America Holdings | Assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients |
| CA3081752A1 (en) * | 2017-11-02 | 2019-05-09 | Prevencio, Inc. | Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes |
| US11009452B2 (en) * | 2018-01-26 | 2021-05-18 | Viavi Solutions Inc. | Reduced false positive identification for spectroscopic quantification |
| ES3017793T3 (en) * | 2019-02-20 | 2025-05-13 | Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol | In vitro method for predicting mortality risk in patients suffering from cardiogenic shock |
| CN110232975A (zh) * | 2019-05-20 | 2019-09-13 | 郑州大学第一附属医院 | 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法 |
| CN110491512A (zh) * | 2019-08-08 | 2019-11-22 | 郑州大学第一附属医院 | 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110970131B (zh) * | 2019-10-24 | 2024-01-26 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
| RU2726314C1 (ru) * | 2019-11-15 | 2020-07-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования |
| RU2760445C1 (ru) * | 2020-11-13 | 2021-11-25 | Виталий Юрьевич Мишланов | Способ диагностики патологических состояний человека |
| WO2022202360A1 (ja) * | 2021-03-23 | 2022-09-29 | テルモ株式会社 | 情報処理装置、情報処理方法およびプログラム |
| CN113342963B (zh) * | 2021-04-29 | 2022-03-04 | 山东大学 | 一种基于迁移学习的服务推荐方法及系统 |
| RU2770550C1 (ru) * | 2021-05-31 | 2022-04-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования сердечно-сосудистого риска с помощью определения уровня эстрогенов |
| EP4500552A2 (en) * | 2022-03-30 | 2025-02-05 | Inflammatix, Inc. | Methods for diagnosing myocardial infarction |
| CN114974576A (zh) * | 2022-07-12 | 2022-08-30 | 曜立科技(北京)有限公司 | 一种基于元数据的心脑血管数疾病诊断管理系统 |
| CN115185936B (zh) | 2022-07-12 | 2023-02-03 | 曜立科技(北京)有限公司 | 一种基于大数据的医疗临床数据质量分析系统 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20080202927A1 (en) | 2000-11-03 | 2008-08-28 | Clinical Micro Sensors, Inc. | Devices and methods for biochip multiplexing |
| US20030134433A1 (en) | 2002-01-16 | 2003-07-17 | Nanomix, Inc. | Electronic sensing of chemical and biological agents using functionalized nanostructures |
| US20060228723A1 (en) | 2002-01-16 | 2006-10-12 | Keith Bradley | System and method for electronic sensing of biomolecules |
| US9234867B2 (en) | 2003-05-16 | 2016-01-12 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
| US20080269346A1 (en) * | 2005-02-17 | 2008-10-30 | University Of Florida Research Foundation, Inc. | B-Blocker Pharmacogenetics in Heart Failure |
| CN101495862A (zh) * | 2005-06-24 | 2009-07-29 | 利兰·斯坦福青年大学托管委员会 | 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物 |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| US20100331200A1 (en) * | 2006-03-31 | 2010-12-30 | Gordon Neal F | Post translational modification pattern analysis |
| EP2924440A3 (en) * | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| WO2008045799A2 (en) | 2006-10-06 | 2008-04-17 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| PL2084543T3 (pl) * | 2006-10-26 | 2018-04-30 | B.R.A.H.M.S Gmbh | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II |
| EP2147115A4 (en) * | 2007-04-16 | 2010-05-05 | CARDIOBIOINDEX / CARDIOBIOSCORE AND THE USE OF THE SPOKING PROTEOME IN CARDIOVASCULAR DIAGNOSTICS | |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| US20100267062A1 (en) * | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| RU2568354C2 (ru) | 2009-06-04 | 2015-11-20 | Конинклейке Филипс Электроникс, Н.В. | Способ и система обеспечения поведенческой терапии для лечения бессонницы |
| JP5678045B2 (ja) * | 2009-06-08 | 2015-02-25 | シンギュレックス・インコーポレイテッド | 高感度バイオマーカーパネル |
| WO2011022628A1 (en) * | 2009-08-20 | 2011-02-24 | The Board Of Regents Of The University Of Texas System | Methods and compositions for diagnosis of acute myocardial infarction (ami) |
| US20110144914A1 (en) * | 2009-12-09 | 2011-06-16 | Doug Harrington | Biomarker assay for diagnosis and classification of cardiovascular disease |
| KR101256928B1 (ko) * | 2010-01-20 | 2013-04-19 | 주식회사디엔에이링크 | 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도 |
| WO2012072595A1 (en) * | 2010-11-30 | 2012-06-07 | Universiteit Gent | Platelet factor 4 variant for the prognosis of cardiovascular outcome in patients having heart disease |
| BR112013022952B1 (pt) | 2011-03-09 | 2020-09-08 | Abionic Sa | Biossensor, matriz compreendendo diversos biossensores, montagem consistindo em um ou diversos biossensores e método para detectar e quantificar a presença de biomoléculas |
| US20140193846A1 (en) * | 2011-04-19 | 2014-07-10 | Scott & White Healthcare | Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease |
| US20140011811A1 (en) * | 2011-10-06 | 2014-01-09 | The United States Government As Represented By The Department Of Veterans Affairs | Myosin binding protein-c for use in methods relating to diastolic heart failure |
| EP2920722B1 (en) * | 2012-11-16 | 2021-01-20 | Siemens Healthcare Diagnostics Inc. | Method to identify optimum coronary artery disease treatment |
| CA2953789A1 (en) | 2013-07-12 | 2015-01-15 | Emory University | Diagnostic assay to predict cardiovascular risk |
| EP3021968B1 (en) | 2013-07-17 | 2018-09-26 | Abionic SA | Method and device for bioassays |
| WO2015085314A2 (en) * | 2013-12-06 | 2015-06-11 | Diadexus, Inc. | Methods for detection of heart failure |
| WO2015171989A1 (en) * | 2014-05-08 | 2015-11-12 | University Of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
| ES2973772T3 (es) | 2014-07-03 | 2024-06-24 | Abionic Sa | Cápsula de cuantificación molecular rápida de una muestra de fluido, tal como sangre completa |
| CN108700596A (zh) | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| JP7310591B2 (ja) | 2019-12-19 | 2023-07-19 | 株式会社オートネットワーク技術研究所 | 駆動装置 |
-
2017
- 2017-02-01 CN CN201780011650.8A patent/CN108700596A/zh active Pending
- 2017-02-01 EP EP25170203.1A patent/EP4574024A3/en active Pending
- 2017-02-01 CN CN202210116587.7A patent/CN114441773A/zh active Pending
- 2017-02-01 MA MA043980A patent/MA43980A/fr unknown
- 2017-02-01 RU RU2018130866A patent/RU2018130866A/ru not_active Application Discontinuation
- 2017-02-01 JP JP2018559674A patent/JP7134870B2/ja active Active
- 2017-02-01 KR KR1020187024496A patent/KR20180101595A/ko not_active Withdrawn
- 2017-02-01 EP EP17748086.0A patent/EP3411720B1/en active Active
- 2017-02-01 BR BR112018015698A patent/BR112018015698A2/pt not_active Application Discontinuation
- 2017-02-01 SG SG11201805906WA patent/SG11201805906WA/en unknown
- 2017-02-01 MX MX2018009304A patent/MX2018009304A/es unknown
- 2017-02-01 AU AU2017214469A patent/AU2017214469A1/en not_active Abandoned
- 2017-02-01 US US16/073,754 patent/US10983135B2/en active Active
- 2017-02-01 CA CA3012192A patent/CA3012192A1/en active Pending
- 2017-02-01 WO PCT/US2017/016081 patent/WO2017136464A1/en not_active Ceased
-
2020
- 2020-10-27 US US17/081,776 patent/US11977083B2/en active Active
-
2021
- 2021-06-10 JP JP2021097387A patent/JP7403498B2/ja active Active
-
2022
- 2022-09-21 JP JP2022150335A patent/JP2022171936A/ja active Pending
-
2023
- 2023-06-21 US US18/339,066 patent/US12146888B2/en active Active
-
2024
- 2024-10-11 US US18/913,852 patent/US20250060374A1/en active Pending
- 2024-12-09 JP JP2024214563A patent/JP2025029196A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791191C1 (ru) * | 2022-12-26 | 2023-03-03 | Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации | Способ оценки клинической значимости фибрилляции предсердий при определении показаний к интервенционному лечению фибрилляции предсердий |
| RU2829792C2 (ru) * | 2023-03-15 | 2024-11-06 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ определения вероятности наличия сердечно-сосудистого заболевания |
Also Published As
| Publication number | Publication date |
|---|---|
| US11977083B2 (en) | 2024-05-07 |
| EP4574024A2 (en) | 2025-06-25 |
| US20250060374A1 (en) | 2025-02-20 |
| WO2017136464A1 (en) | 2017-08-10 |
| EP4574024A3 (en) | 2025-10-08 |
| US12146888B2 (en) | 2024-11-19 |
| US20210072260A1 (en) | 2021-03-11 |
| EP3411720B1 (en) | 2025-04-16 |
| EP3411720A4 (en) | 2019-08-14 |
| EP3411720A1 (en) | 2018-12-12 |
| US20230341418A1 (en) | 2023-10-26 |
| BR112018015698A2 (pt) | 2018-12-26 |
| CN108700596A (zh) | 2018-10-23 |
| CA3012192A1 (en) | 2017-08-10 |
| CN114441773A (zh) | 2022-05-06 |
| JP2019507354A (ja) | 2019-03-14 |
| JP7403498B2 (ja) | 2023-12-22 |
| EP3411720C0 (en) | 2025-04-16 |
| JP2022171936A (ja) | 2022-11-11 |
| KR20180101595A (ko) | 2018-09-12 |
| SG11201805906WA (en) | 2018-08-30 |
| JP7134870B2 (ja) | 2022-09-12 |
| JP2025029196A (ja) | 2025-03-05 |
| US20190369120A1 (en) | 2019-12-05 |
| JP2021128177A (ja) | 2021-09-02 |
| AU2017214469A1 (en) | 2018-07-26 |
| US10983135B2 (en) | 2021-04-20 |
| MA43980A (fr) | 2018-12-12 |
| MX2018009304A (es) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018130866A (ru) | Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений | |
| Barberi et al. | The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: A systematic review | |
| Jaffe et al. | Biomarkers in acute cardiac disease: the present and the future | |
| Hochholzer et al. | Novel biomarkers in cardiovascular disease: update 2010 | |
| Felker et al. | A standardized definition of ischemic cardiomyopathy for use in clinical research | |
| Lee et al. | Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia | |
| Wang | New cardiovascular risk factors exist, but are they clinically useful? | |
| JP7762680B2 (ja) | 急性冠症候群のリスクを推定するための決定木ベースのシステム及び方法 | |
| JP2019507354A5 (enExample) | ||
| Mantovani et al. | Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography | |
| Niu et al. | Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction | |
| Parikh et al. | Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice | |
| Liu et al. | Prognostic role of heart-type fatty acid binding protein in pulmonary embolism: a meta-analysis | |
| Li et al. | Fatty acid binding protein 4 has prognostic value in peripheral artery disease | |
| Abubakar et al. | Comprehensive quality analysis of conventional and novel biomarkers in diagnosing and predicting prognosis of coronary artery disease, acute coronary syndrome, and heart failure, a comprehensive literature review | |
| Singh et al. | The role of biomarkers in the prognosis and risk stratification in heart failure: A systematic review | |
| Canney et al. | Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease | |
| Gegenhuber et al. | B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure | |
| Valledor et al. | Correlation between donor-derived cell-free DNA and tissue gene expression in heart transplant patients undergoing for-cause endomyocardial biopsies | |
| Behnes et al. | Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema | |
| Nagata et al. | Serum N-terminal pro-B-type natriuretic peptide as a predictor for future development of atrial fibrillation in a general population: the Hisayama Study | |
| Kidher et al. | Aortic stiffness as a marker of cardiac function and myocardial strain in patients undergoing aortic valve replacement | |
| Zhu et al. | Serum IGFBP5 as a predictor of major adverse cardiac events in patients with acute myocardial infarction | |
| Clerico et al. | New and emerging biomarkers of heart failure | |
| RU2566212C1 (ru) | Способ многофакторного прогнозирования отдаленных неблагоприятных исходов у пациентов, перенесших острый коронарный синдром со стойким подъемом сегмента st |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200203 |